Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Amphastar Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. Analysts expressed disappointment at the Company’s announcement and Amphastar has still not responded to the CRL. Following this news, Amphastar’s stock price fell by $7.31 per share, or approximately 13% to close at $46.09 per share on November 7, 2024.
In order to be eligible to join the AMPH class action lawsuit, you must have incurred a loss on shares of Amphastar Pharmaceuticals, Inc. purchased during the class period listed above.
TOP
